Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.